{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:36:20Z","timestamp":1792805780609,"version":"4.5.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kisupplements.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Supplements"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.kisu.2026.01.002","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:13:49Z","timestamp":1784538829000},"page":"14-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Management of IgA nephropathy and the expanding role of immunomodulation"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1130-5486","authenticated-orcid":false,"given":"Pietro A.","family":"Canetta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather N.","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kisu.2026.01.002_bib1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.002_bib2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.002_bib3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ki.2015.322","article-title":"The MEST score provides earlier risk prediction in lgA nephropathy","volume":"89","author":"Barbour","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.002_bib4","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.002_bib5","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a new international risk-prediction tool in IgA nephropathy","volume":"179","author":"Barbour","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.kisu.2026.01.002_bib6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.kint.2022.02.042","article-title":"Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy","volume":"102","author":"Barbour","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.002_bib7","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.002_bib8","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/ndt\/gfr527","article-title":"Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population","volume":"27","author":"Le","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.002_bib9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1053\/j.ajkd.2023.12.016","article-title":"Time-varying proteinuria and progression of IgA nephropathy: a cohort study","volume":"84","author":"Tang","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2026.01.002_bib10","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ki.2009.168","article-title":"The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility","volume":"76","author":"Roberts","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.002_bib11","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.3390\/ijerph16183317","article-title":"Individual and environmental factors associated with proteinuria in Korean children: a multilevel analysis","volume":"16","author":"Kim","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.kisu.2026.01.002_bib12","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.kisu.2026.01.002_bib13","author":"Lafayette"},{"key":"10.1016\/j.kisu.2026.01.002_bib14","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.kisu.2026.01.002_bib15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kisu.2026.01.002_bib16","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kisu.2026.01.002_bib17","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.002_bib18","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s10157-023-02316-2","article-title":"Prognostic factors of IgA nephropathy presenting with mild proteinuria at the time of diagnosis (a multicenter cohort study)","volume":"27","author":"Shirai","year":"2023","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.kisu.2026.01.002_bib19","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2026.01.002_bib20","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2019010007","article-title":"GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials","volume":"30","author":"Inker","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.002_bib21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2026.01.002_bib22","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1016\/j.ekir.2022.09.017","article-title":"One-year estimated GFR slope independently predicts clinical benefit in immunoglobulin A nephropathy","volume":"7","author":"Lafayette","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.002_bib23","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/ki.2014.63","article-title":"Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments","volume":"86","author":"Coppo","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.002_bib24","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","article-title":"KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV)","volume":"108","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.002_bib25","series-title":"Molecular and Genetic Basis of Renal Disease","first-page":"373","article-title":"Molecular mechanisms of proteinuria","author":"Jefferson","year":"2008"},{"key":"10.1016\/j.kisu.2026.01.002_bib26","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1016\/j.ekir.2024.07.031","article-title":"Correlation of urinary soluble CD163 levels with disease activity and treatment response in IgA nephropathy","volume":"9","author":"Li","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.002_bib27","article-title":"Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression","volume":"14","author":"Maixnerova","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.kisu.2026.01.002_bib28","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/cei.12461","article-title":"Combined C4d and CD3 immunostaining predicts immunoglobulin (Ig)A nephropathy progression","volume":"179","author":"Faria","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.kisu.2026.01.002_bib29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","article-title":"The pathogenesis of IgA nephropathy and implications for treatment","volume":"21","author":"Cheung","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kisu.2026.01.002_bib30","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.3390\/jcm14093263","article-title":"Modern biomarkers in IgA nephropathy and their potential in paediatric research","volume":"14","author":"Such-Gruchot","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.kisu.2026.01.002_bib31","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s10157-013-0921-6","article-title":"Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy","volume":"18","author":"Suzuki","year":"2014","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.kisu.2026.01.002_bib32","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1681\/ASN.2012010053","article-title":"Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy","volume":"23","author":"Berthoux","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.002_bib33","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3389\/fimmu.2019.00504","article-title":"The emerging role of complement proteins as a target for therapy of IgA nephropathy","volume":"10","author":"Rizk","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.kisu.2026.01.002_bib34","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae395","article-title":"Urine complement-related proteins in IgA nephropathy and IgA vasculitis nephritis, possible biomarkers of disease activity","volume":"18","author":"Nurmi","year":"2025","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kisu.2026.01.002_bib35","article-title":"The role of mononuclear phagocyte system in IgA nephropathy: pathogenesis and prognosis","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.kisu.2026.01.002_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.769802","article-title":"Urinary soluble CD163 levels predict IgA nephropathy remission status","volume":"12","author":"Gong","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.kisu.2026.01.002_bib37","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/01.ASN.0000068460.37369.DC","article-title":"Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial","volume":"14","author":"Praga","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.002_bib38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.kisu.2026.01.004","article-title":"The expanding role of biomarkers in the management of IgA nephropathy","volume":"15","author":"Jain","year":"2026","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kisu.2026.01.002_bib39","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","article-title":"Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study","volume":"47","author":"Li","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2026.01.002_bib40","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1681\/ASN.2006040347","article-title":"IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria","volume":"18","author":"Coppo","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.002_bib41","article-title":"Non-immunosuppressive treatment for IgA nephropathy","volume":"2","author":"Tunnicliffe","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.kisu.2026.01.002_bib42","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1159\/000013619","article-title":"Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy","volume":"20","author":"Nakamura","year":"2000","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kisu.2026.01.002_bib43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ndt\/gfi265","article-title":"Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases","volume":"21","author":"Ruiz-Ortega","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.002_bib44","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.kisu.2026.01.002_bib45","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/dom.13965","article-title":"What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?","volume":"22","author":"Sridhar","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kisu.2026.01.002_bib46","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kisu.2026.01.002_bib47","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kisu.2026.01.002_bib48","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.002_bib49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","article-title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial","volume":"12","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kisu.2026.01.002_bib50","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.ekir.2023.07.023","article-title":"Targeting the endothelin A receptor in IgA nephropathy","volume":"8","author":"Kohan","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.002_bib53","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.kisu.2026.03.001","article-title":"Approved therapies in the IgA nephropathy armamentarium: a summary of the evidence","volume":"15","author":"Norouzi","year":"2026","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kisu.2026.01.002_bib54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.kisu.2026.01.003","article-title":"IgA nephropathy: an overview of the disease, its pathophysiology, and involvement of the gut-kidney axis","volume":"15","author":"Cheung","year":"2026","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kisu.2026.01.002_bib63","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kisu.2026.01.002_bib64","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ekir.2023.11.026","article-title":"Novel treatment paradigms: primary IgA nephropathy","volume":"9","author":"Selvaskandan","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.002_bib67","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.kisu.2026.01.001","article-title":"IgA nephropathy management: what does the future hold?","volume":"15","author":"Tang","year":"2026","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kisu.2026.01.002_bib68","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1681\/ASN.2011111112","article-title":"Corticosteroid therapy in IgA nephropathy","volume":"23","author":"Lv","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.002_bib69","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.kisu.2026.01.002_bib70","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.kisu.2026.01.002_bib71","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1681\/ASN.2017060713","article-title":"Effects of two immunosuppressive treatment protocols for IgA nephropathy","volume":"29","author":"Rauen","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.002_bib72","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/ndt\/gfq674","article-title":"A meta-analysis of the clinical remission rate and long-term efficacy of tonsillectomy in patients with IgA nephropathy","volume":"26","author":"Wang","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.002_bib73","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/j.ajkd.2014.06.036","article-title":"Tonsillectomy for IgA nephropathy: a meta-analysis","volume":"65","author":"Liu","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2026.01.002_bib74","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11255-016-1432-7","article-title":"Long-term efficacy of tonsillectomy as a treatment in patients with IgA nephropathy: a meta-analysis","volume":"49","author":"Duan","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.kisu.2026.01.002_bib75","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/ndt\/gfu020","article-title":"A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy","volume":"29","author":"Kawamura","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.002_bib76","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3109\/0886022X.2015.1128251","article-title":"The efficacy of tonsillectomy on clinical remission and relapse in patients with IgA nephropathy: a randomized controlled trial","volume":"38","author":"Yang","year":"2016","journal-title":"Ren Fail"},{"key":"10.1016\/j.kisu.2026.01.002_bib77","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000441852","article-title":"Tonsillectomy in a European cohort of 1,147 patients with IgA nephropathy","volume":"132","author":"Feehally","year":"2016","journal-title":"Nephron"},{"key":"10.1016\/j.kisu.2026.01.002_bib78","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.kisu.2026.01.002_bib79","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1523-1755.2005.00460.x","article-title":"Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy","volume":"68","author":"Tang","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.002_bib80","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ki.2009.499","article-title":"Long-term study of mycophenolate mofetil treatment in IgA nephropathy","volume":"77","author":"Tang","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.002_bib81","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.kisu.2026.01.002_bib82","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","article-title":"Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial","volume":"69","author":"Hou","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2026.01.002_bib83","doi-asserted-by":"crossref","first-page":"452","DOI":"10.23876\/j.krcp.21.146","article-title":"A multicenter, randomized, open-label, comparative, phase IV study to evaluate the efficacy and safety of combined treatment with mycophenolate mofetil and corticosteroids in advanced immunoglobulin A nephropathy","volume":"41","author":"Han","year":"2022","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.kisu.2026.01.002_bib84","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","article-title":"Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study","volume":"65","author":"Maes","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.002_bib85","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","article-title":"Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial","volume":"20","author":"Frisch","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.002_bib86","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","article-title":"Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy","volume":"66","author":"Hogg","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2026.01.002_bib87","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.semarthrit.2013.01.001","article-title":"Multifaceted effects of hydroxychloroquine in human disease","volume":"43","author":"Olsen","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.kisu.2026.01.002_bib88","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","article-title":"Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial","volume":"74","author":"Liu","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2026.01.002_bib89","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s40620-023-01733-6","article-title":"Hydroxychloroquine in nephrology: current status and future directions","volume":"36","author":"Rao","year":"2023","journal-title":"J Nephrol"},{"key":"10.1016\/j.kisu.2026.01.002_bib90","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1080\/0886022X.2021.2000875","article-title":"Hydroxychloroquine in IgA nephropathy: a systematic review","volume":"43","author":"Stefan","year":"2021","journal-title":"Ren Fail"},{"key":"10.1016\/j.kisu.2026.01.002_bib92","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/s41588-023-01422-x","article-title":"Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy","volume":"55","author":"Kiryluk","year":"2023","journal-title":"Nat Genet"},{"key":"10.1016\/j.kisu.2026.01.002_bib93","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/0886022X.2018.1532907","article-title":"The influence of environmental factors on clinical pathological changes of patients with immunoglobulin A nephropathy from different areas of China","volume":"40","author":"Fan","year":"2018","journal-title":"Ren Fail"},{"key":"10.1016\/j.kisu.2026.01.002_bib94","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.ekir.2020.08.009","article-title":"Why target the gut to treat IgA nephropathy?","volume":"5","author":"Barratt","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.002_bib95","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/iji.12561","article-title":"Immunological drivers of IgA nephropathy: exploring the mucosa-kidney link","volume":"49","author":"Selvaskandan","year":"2022","journal-title":"Int J Immunogenet"},{"key":"10.1016\/j.kisu.2026.01.002_bib96","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.002_bib97","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/jcm13010123","article-title":"An update on the genetics of IgA nephropathy","volume":"13","author":"Xu","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.kisu.2026.01.002_bib98","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1172\/JCI74475","article-title":"The genetics and immunobiology of IgA nephropathy","volume":"124","author":"Kiryluk","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kisu.2026.01.002_bib99","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2215\/CJN.07260713","article-title":"Glomerular diseases: emerging tests and therapies for IgA nephropathy","volume":"9","author":"Canetta","year":"2014","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Kidney International Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215717162600002X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215717162600002X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T10:46:50Z","timestamp":1786013210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215717162600002X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S215717162600002X"],"URL":"https:\/\/doi.org\/10.1016\/j.kisu.2026.01.002","relation":{},"ISSN":["2157-1716"],"issn-type":[{"value":"2157-1716","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of IgA nephropathy and the expanding role of immunomodulation","name":"articletitle","label":"Article Title"},{"value":"Kidney International Supplements","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2026.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2026.01.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2026.01.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2026.01.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2026.03.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2025.12.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}